Skip to content

A Post-Market Clinical Follow-up Study of the Auto Tissue Berlin Equine Matrix Patch™: The All-Patch Study

A Post-Market Clinical Follow-up Study of the Auto Tissue Berlin Equine Matrix Patch™: The All-Patch Study - ATB-1

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00023620
Enrollment
100
Registered
2021-01-26
Start date
2021-02-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart tissue defects Q20-Q28

Interventions

Group 1: Cardiac or vascular surgery for the expansion and/or repair of heart or Vascular Tissue Defects

Sponsors

Auto Tissue Berlin GmbH
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with cardiac or vascular disease for which surgical repair involving a tissue patch is indicated. 2. Written consent of the patient or the legal guardian.

Exclusion criteria

Exclusion criteria: 1. Patients in whom the treating physician or surgeon believes that the risks of using a xenograft for repair of congenital or acquired cardiac or vascular tissue defects outweigh the benefits. 2. Patient is participating in an investigational drug or device study that has not reached the primary endpoint or that interferes with the current study endpoints. 3. Any condition that in the judgment of the investigators would interfere with the patient’s ability to provide informed consent, comply with study instructions, place the patient at increased risk, or which might confound interpretation of study results.

Design outcomes

Primary

MeasureTime frame
The primary outcome of this study is to prospectively evaluate the safety of the equine matrix patch. Safety defined as rates of device and procedure related serious adverse events post-implantation of the Matrix Patch at 6 months post-implantation.

Secondary

MeasureTime frame
Secondary outcomes of this study are the evaluation of the usability and the performance of the equine matrix patches during cardiovascular surgery. Usability: Defined as the satisfaction with and ease of use of the Matrix Patch as reported by the surgeon performing the surgery in which the Matrix Patch was used. Performance: Defined as the incidence of repeat surgery to repair the abnormality for which the Matrix Patch was used, and the absence of adverse outcomes related to the Matrix Patch (including death) assessed at 1 year.

Countries

Germany, Slovakia

Contacts

Public ContactHans-Joachim Schäfers

Klinik für Thorax- und Herz-Gefäßchirurgie Universitätsklinik Homburg

h-j.schaefers@uks.eu06841 / 1632000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026